(Cefepime + Taniborbactam hydrochloride) is a small molecule commercialized by Everest Medicines, with a leading Phase III program in Pyuria. According to Globaldata, it is involved in 8 clinical trials, of which 7 were completed, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of (Cefepime + Taniborbactam hydrochloride)’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for (Cefepime + Taniborbactam hydrochloride) is expected to reach an annual total of $14 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
(Cefepime + Taniborbactam hydrochloride) Overview
Fixed dose combination of cefepime and taniborbactam hydrochloride (VNRX-5133) is under development for the treatment of multi-drug resistant (MDR) gram-negative infections such as carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa infections, complicated urinary tract infections (cUTI) including acute pyelonephritis, pyuria, hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. It is administered intravenously as a powder for solution . The therapeutic candidate acts by targeting beta lactamase and penicillin binding protein 2.
It was also under development for the treatment of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI) including acute pyelonephritis.
Everest Medicines Overview
Everest Medicines is a biopharmaceutical company. It discovers, develops, manufactures and commercializes transformative pharmaceutical products and vaccines. The company’s products include nefecon, an oral-release formulation that treats IgA nephropathy; and Xerava (eravacycline), a novel fluorocycline intravenous antibiotic for treating complicated intra-abdominal infections (CIAI). Its pipeline products include zetomipzomib (KZR-616), which targets lupus nephritis; EVER001 (XNW1011) for glomerulonephritis; cefepime-taniborbactam, which treats complicated urinary tract infection (CUTI); SPR206 (EVER206) for gram-negative infections; etrasimod targeting ulcerative colitis; and discovery cancer platform products. The company operates through its subsidiaries in Hong Kong, China, the US and South Korea, among others. Everest Medicines is headquartered in Shanghai, China.
The company reported revenues of (Renminbi) CNY125.9 million for the fiscal year ended December 2023 (FY2023), compared to a revenue of CNY12.8 million in FY2022. The operating loss of the company was CNY932.7 million in FY2023, compared to an operating loss of CNY256.8 million in FY2022. The net loss of the company was CNY844.5 million in FY2023, compared to a net loss of CNY247.3 million in FY2022.
For a complete picture of (Cefepime + Taniborbactam hydrochloride)’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
